{"id":4155,"company":{"country":"CH","currency":"USD","exchange":"SWISS EXCHANGE","ipo":"2001-05-07","marketCap":195259,"name":"Novartis AG","phone":"41613241111","outstanding":1956.49,"symbol":"NVS","website":"https://www.novartis.com/","industry":"Pharmaceuticals"},"price":112.53625,"year":2024,"month":8,"day":3,"weekday":"Saturday","title":"Corporate Governance Practices of Novartis AG","date":"2024-08-03","url":"/posts/2024/08/03/NVS","content":[{"section":"Board Composition","text":"Novartis AG has a diverse board composition, consisting of individuals with expertise in various fields including pharmaceuticals, finance, and healthcare. The board is composed of both independent directors and executive directors, ensuring a balanced representation of interests. The independent directors bring an outside perspective, which enhances the objectivity and effectiveness of board decision-making."},{"section":"Executive Compensation","text":"Novartis AG has a responsible approach to executive compensation. The company believes in aligning executive pay with both short-term and long-term performance objectives. The compensation packages are designed to incentivize executives to deliver sustainable growth and shareholder value, while also taking into consideration external market benchmarks. Novartis AG also discloses detailed information about executive compensation in its annual reports, demonstrating transparency and accountability."},{"section":"Board Committees","text":"Novartis AG has several board committees responsible for specific areas of oversight. These committees include the Audit and Compliance Committee, the Compensation Committee, and the Nomination and Corporate Governance Committee. These committees evaluate and make recommendations on matters related to financial reporting, executive compensation, and board composition respectively. The existence of these committees enhances the effectiveness of corporate governance, providing specialized expertise and independent oversight."},{"section":"Shareholder Engagement","text":"Novartis AG actively engages with its shareholders to ensure transparency and accountability. The company holds regular meetings with shareholders, providing them with a platform to voice their concerns and ask questions. Novartis AG also conducts an annual general meeting where shareholders can vote on important matters. This open communication fosters a sense of trust and enables shareholders to actively participate in the decision-making process."},{"section":"Ethics and Compliance","text":"Novartis AG places a strong emphasis on ethics and compliance in its corporate governance practices. The company has a comprehensive Code of Conduct that outlines the expected behavior for employees, directors, and executives. Novartis AG also maintains a robust compliance program to ensure adherence to laws, regulations, and internal policies. The company regularly conducts training programs and audits to promote a culture of ethical behavior and mitigate compliance risks."},{"section":"Conclusion","text":"Novartis AG demonstrates strong corporate governance practices through its well-diversified board composition, responsible executive compensation approach, active shareholder engagement, and focus on ethics and compliance. These practices contribute to sustainable growth, shareholder value, and the overall success of the company."}],"tags":["LongSignals","Long","Pharmaceuticals"],"news":[{"category":"company","date":1722606300,"headline":"Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues","id":129105699,"image":"https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795","symbol":"NVS","publisher":"Yahoo","summary":"Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.","url":"https://finance.yahoo.com/news/alnylam-alny-q2-earnings-beat-134500527.html"},{"category":"company","date":1722587641,"headline":"Q2 2024 Ionis Pharmaceuticals Inc Earnings Call","id":129095318,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"NVS","publisher":"Yahoo","summary":"Q2 2024 Ionis Pharmaceuticals Inc Earnings Call","url":"https://finance.yahoo.com/news/q2-2024-ionis-pharmaceuticals-inc-083401992.html"},{"category":"company","date":1722572280,"headline":"Novartis just downgraded at Stifel, here's why","id":129120770,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3582982550"},{"category":"company","date":1722480600,"headline":"Novartis sues FDA for approving Entresto generic","id":129089907,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3581740704"},{"category":"company","date":1722465600,"headline":"Artisan Global Value Fund Q2 2024 Commentary","id":129053363,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399575283/image_1399575283.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"During Q2 2024, the Artisan Global Value Fund (Investor Class) returned 1.5%. Click here to read the full fund commentary.","url":"https://seekingalpha.com/article/4708903-artisan-global-value-fund-q2-2024-commentary"},{"category":"company","date":1722337200,"headline":"Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update","id":129001659,"image":"https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081","symbol":"NVS","publisher":"Yahoo","summary":"– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novar","url":"https://finance.yahoo.com/news/arvinas-reports-second-quarter-2024-110000118.html"},{"category":"company","date":1722328561,"headline":"Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges","id":129002115,"image":"","symbol":"NVS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4707941-legend-biotechs-promising-car-t-therapies-face-valuation-and-cash-burn-challenges"},{"category":"company","date":1722327144,"headline":"FDA grants priority review for Novartis’ leukaemia treatment","id":128999349,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/Novartis_shutterstock_1940836891.jpg","symbol":"NVS","publisher":"Yahoo","summary":"The decision is based on the data from the Phase III ASC4FIRST clinical trial.","url":"https://www.pharmaceutical-technology.com/news/fda-novartis-leukaemia-treatment/"},{"category":"company","date":1722315608,"headline":"TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance","id":128999077,"image":"","symbol":"NVS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4707904-tg-therapeutics-upcoming-q2-pressure-on-briumvi-to-perform-as-share-price-hits-resistance"},{"category":"company","date":1722257580,"headline":"Novartis' Scemblix granted FDA Priority Review status for front-line CML","id":128992774,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3576600195"},{"category":"company","date":1722255579,"headline":"AbbVie: Growth Is Still A Better Choice","id":128984439,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1127277566/image_1127277566.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"AbbVie's impressive Q2 2024 financial results show surging sales in immunology and neuroscience. Read why I continue to cover ABBV stock with a 'Buy' rating.","url":"https://seekingalpha.com/article/4707698-abbvie-growth-is-still-a-better-choice"},{"category":"company","date":1722238080,"headline":"Novartis receives FDA priority review for CML in adults","id":129022181,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3576988252"},{"category":"company","date":1721994480,"headline":"Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment","id":128931467,"image":"https://media.gettyimages.com/id/2161144503/photo/hands-lab-and-medical-research-with-tablet-science-and-internet-for-breakthrough-in-medicine.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=rSeqfu2rWoglg7VuNtvJ3532xcENZiabU2Lmsbh19n4=","symbol":"NVS","publisher":"SeekingAlpha","summary":"Stay informed about the latest developments in spinal muscular atrophy and obesity treatments, with a projected market growth reaching billions by 2032.","url":"https://seekingalpha.com/article/4707148-biohaven-taldefgrobep-alfa-might-have-a-place-beyond-sma-treatment"},{"category":"company","date":1721985300,"headline":"Aristotle International Equity ADR Q2 2024 Commentary","id":128929273,"image":"","symbol":"NVS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4707100-aristotle-international-equity-adr-q2-2024-commentary"},{"category":"company","date":1721895558,"headline":"Dren Bio and Novartis link on bispecific antibodies for cancer","id":128904334,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/Novartis-shutterstock_2210307289.jpg","symbol":"NVS","publisher":"Yahoo","summary":"Dren Bio is eligible to receive $2.85bn in preclinical, clinical, regulatory and commercial milestone payments.","url":"https://www.pharmaceutical-technology.com/news/dren-bio-novartis-antibodies-cancer/"},{"category":"company","date":1721831160,"headline":"Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?","id":128881071,"image":"https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","symbol":"NVS","publisher":"Yahoo","summary":"On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.","url":"https://finance.yahoo.com/news/beat-cards-incyte-incy-q2-142600358.html"},{"category":"company","date":1721820240,"headline":"Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board","id":128883830,"image":"https://www.biopharmadive.com/imgproxy/aFO49QT1-ytbqrjsghNN87eKIlQQL6Xv-4smpw2yyUw/g:nowe:909:0/c:6097:3444/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODM5MjE3OTMuanBn.webp","symbol":"NVS","publisher":"Yahoo","summary":"The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.” Elsewhere, Geron is losing its commercial chief and Biovectra will sell to Agilent for $925 million.","url":"https://www.biopharmadive.com/news/novartis-dren-bio-langer-moderna-board-biovectra-agilent/722086/"},{"category":"company","date":1721808120,"headline":"Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer","id":128891241,"image":"","symbol":"NVS","publisher":"Business Wire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=mja13of2u6"},{"category":"company","date":1721785320,"headline":"Novartis to collaborate with Dren Bio on bispecific antibody therapies","id":128891243,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3570101621"},{"category":"company","date":1721763136,"headline":"Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking","id":128866392,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1871083321/image_1871083321.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Sangamo Therapeutics is almost out of cash, and at risk of bankruptcy.Â Learn the reasons whyÂ an investment in the SGMO stock is unsuitable right now.","url":"https://seekingalpha.com/article/4705968-sangamo-therapeutics-a-bust-or-billion-dollar-valuation-in-the-remaking"},{"category":"company","date":1721737020,"headline":"Novartis AG (NOVN) Gets a Hold from Berenberg Bank","id":128847412,"image":"","symbol":"NVS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3567885764"},{"category":"company","date":1721719800,"headline":"Novartis price target raised by CHF 9 at Berenberg","id":128891244,"image":"","symbol":"NVS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3568973833"},{"category":"company","date":1721702700,"headline":"AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife","id":128857897,"image":"","symbol":"NVS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3567973637"},{"category":"company","date":1721653211,"headline":"These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar","id":128831674,"image":"https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c","symbol":"NVS","publisher":"Yahoo","summary":"Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.","url":"https://finance.yahoo.com/news/2-medical-stocks-could-beat-130011272.html"},{"category":"company","date":1721650759,"headline":"Johnson \u0026 Johnson: Seriously Undervalued At Peak Pessimism","id":128832494,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220083268/image_1220083268.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"Johnson \u0026 Johnson's Q2 results exceeded expectations, driven by strong oncology and immunology sales. Read why I continue to cover JNJ stock with a Strong Buy.","url":"https://seekingalpha.com/article/4705518-johnson-and-johnson-seriously-undervalued-at-peak-pessimism"},{"category":"company","date":1721640059,"headline":"Healthcare 2024 Second Half Outlook","id":128830586,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536","symbol":"NVS","publisher":"SeekingAlpha","summary":"While the healthcare index underperformed the broader market, there are favorable indications for the second half. Read more to see my thoughts on the sector.","url":"https://seekingalpha.com/article/4705471-healthcare-2024-second-half-outlook"},{"category":"company","date":1721541600,"headline":"Here are Big Pharma’s leading blockbuster makers","id":128822866,"image":"","symbol":"NVS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3565745324"},{"category":"company","date":1721447403,"headline":"Novartis: Another Beat, Another Raise","id":128808929,"image":"https://media.gettyimages.com/id/2159351681/photo/view-of-novartis-company-office-with-logo-sign-biotech-industry.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=ebMvNXL6EvVm7XVhbFUWPvf1x5AaBih5VVgVXarDtZw=","symbol":"NVS","publisher":"SeekingAlpha","summary":"Investors can benefit from Novartis' strong revenue growth, margin expansion, buybacks, dividends, and raised guidance. Read more on NVS stock here.","url":"https://seekingalpha.com/article/4705254-novartis-another-beat-another-raise"}]}